Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus (Vulgaris and Foliaceus)

NCT03334058 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT03334058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03334058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus (Vulgaris and Foliaceus)
Lead sponsor
argenx
Phase
Phase 2
Overall status
Completed
Start date
October 18, 2017
Completion date
October 28, 2020
Enrollment
34 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pemphigus foliaceus, pemphigus vulgaris